title: Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy.
abstract: As our understanding of cancer pathophysiology has increased, so have the number of targeted therapeutic agents available. By targeting specific molecules involved in tumorigenesis, targeted therapeutic agents offer the potential for significant efficacy against tumor cells while minimizing the adverse effects. We highlight the recently recognized ophthalmic complications of targeted cancer therapy, as well as recently recognized complications of traditional chemotherapeutic agents.
authors.affiliation: Orbital Oncology and Ophthalmic Plastic Surgery Program, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas; American University of Beirut Medical Center, Beirut, Lebanon.
authors.forename: Wajiha J
authors.initials: WJ
authors.lastname: Kheir
authors.affiliation: Orbital Oncology and Ophthalmic Plastic Surgery Program, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Sniegowski
authors.affiliation: Orbital Oncology and Ophthalmic Plastic Surgery Program, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Ophthalmology, Stanford University, Palo Alto, California.
authors.forename: Tarek
authors.initials: T
authors.lastname: El-Sawy
authors.affiliation: Orbital Oncology and Ophthalmic Plastic Surgery Program, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Alexa
authors.initials: A
authors.lastname: Li
authors.affiliation: Orbital Oncology and Ophthalmic Plastic Surgery Program, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: besmaeli@mdanderson.org.
authors.forename: Bita
authors.initials: B
authors.lastname: Esmaeli
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D005128:Eye Diseases / Q000139:chemically induced*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: cancer therapy; ocular adverse effect; targeted therapy